Wald, Ron
Kirkham, Brian
daCosta, Bruno R.
Ghamarian, Ehsan
Adhikari, Neill K. J.
Beaubien-Souligny, William
Bellomo, Rinaldo
Gallagher, Martin P.
Goldstein, Stuart
Hoste, Eric A. J.
Liu, Kathleen D.
Neyra, Javier A.
Ostermann, Marlies
Palevsky, Paul M.
Schneider, Antoine
Vaara, Suvi T.
Bagshaw, Sean M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
IDEAL-ICU in Context
https://doi.org/10.2215/cjn.01180119
Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial
https://doi.org/10.1186/s13054-022-04229-0
Funding for this research was provided by:
Canadian Institutes of Health Research
Article History
Received: 17 July 2022
Accepted: 19 October 2022
First Online: 24 November 2022
Declarations
:
: The STARRT-AKI trial was approved by Research Ethics Boards at all participating centers. Informed consent was obtained from participants and/or substitute decision makers. At sites where the Ethics Board provided approval, deferred or waived consent was utilized.
: All members of the writing committee agreed to publication of this manuscript.
: Ron Wald has received speaker fees an unrestricted research funding from Baxter. MO has received speaker fees and research support from Fresenius Medical Care and Baxter and research funding from Biomerieux. WBS has received speaker fees from Baxter. AS has received speaker fees and research from Fresenius Medical Care and B Braun Avitum and research funding from B Braun Avitum.